Because it is not biomarker directed, lenvatinib plus pembrolizumab remains broadly useful even as HER2-targeted ADCs enter recurrent uterine cancer.
Videos
Ayal Aizer, MD, MHS, explains how expanded trial data have broadened eligibility for stereotactic radiosurgery in patients with brain metastases, including higher tumor counts.
The faculty review patient-reported outcomes, subgroup consistency, and biomarker testing before introducing the second pivotal trial.
Lizza Hendriks, MD, PhD, discussed why excluding patients with brain metastases from clinical trials is no longer ethical.
Sunil Singhal, MD, explained how a fluorescent dye technology helps surgeons see and remove tumors more completely.
Between the Lines
Between the Lines
Between the Lines
Between the Lines
Between the Lines
Between the Lines
Between the Lines
Between the Lines
Between the Lines
The platinum-free interval is prognostic but not predictive for lenvatinib plus pembrolizumab, Susana Campos, MD, MPH, told CancerNetwork.
Experts compared outcomes for NALIRIFOX in patients with metastatic pancreatic cancer based on real-world and clinical trial data.
Five-year follow-up showed 37% overall survival rate with lenvatinib plus pembrolizumab in dMMR endometrial cancer.
Up to 55% of endometrial tumors show HER2/neu heterogeneity, explained Susana Campos, MD, MPH, making biopsy at recurrence key for ADC eligibility.
Andrew Evens, DO & Joanna Rhodes, MD, on CLL's transformation, CAR-T vs bispecifics, Hodgkin survivorship, and delivering world-class lymphoma care across NJ.
Experts discussed proactive strategies for managing diarrhea and making dose reduction decisions with NALIRIFOX in pancreatic cancer.
In the third debate round of this Cancer Network Face Off on advanced hepatocellular carcinoma (HCC), moderator Rachna T. Shroff, MD, presents a Child-Pugh A, BCLC stage B patient eligible for locoregional therapy, asking whether clinicians should prioritize locoregional treatment or introduce systemic therapy earlier.
In the second debate round of this Cancer Network Face Off on advanced hepatocellular carcinoma (HCC), moderator Rachna T. Shroff, MD, presents a treatment-naive patient with Child-Pugh B7, BCLC stage C disease and compromised liver function, asking how limited liver reserve should influence frontline selection.
A retrospective series found a 75% response rate adding lenvatinib after pembrolizumab progression in dMMR endometrial cancer, said Susana Campos, MD, MPH.
Experts discussed how NALIRIFOX compares with FOLFIRINOX and gemcitabine/nab-paclitaxel as frontline therapy for metastatic pancreatic cancer.
Barbara Burtness, MD, outlined the rationale behind OrigAMI-4 eligibility criteria and how tumor boards can select patients with HNSCC for amivantamab.
Following the MAJESTEC-3 presentation, the faculty discuss how the trial findings may influence the evolving treatment landscape for relapsed/refractory multiple myeloma (R/R MM).
Treatment until progression may not be the way forward with bispecific antibodies, according to Hans Lee, MD.
Dr. Harsh Parmar presents results from the phase 3 MAJESTEC-3 trial evaluating the combination of teclistamab and daratumumab versus standard daratumumab-based regimens in patients with relapsed/refractory multiple myeloma (R/R MM) who had received one to three prior lines of therapy.
Advertisement
Advertisement
Trending on CancerNetwork
1
How Fluorescent Tracers Could Transform Lung Cancer Surgery
2
Platinum-Free Interval Does Not Predict IO Response in Endometrial Cancer
3
Five-Year KEYNOTE-775 Data Confirm Durable Benefit With Lenvatinib Combo
4
Teclistamab Combo Earns EU Approval in Relapsed/Refractory Multiple Myeloma
5